



# One-pot synthesis of non-symmetric tetraoxanes with the $\text{H}_2\text{O}_2$ /MTO/fluorous alcohol system<sup>☆</sup>

Jernej Iskra,<sup>a</sup> Danièle Bonnet-Delpon<sup>b,\*</sup> and Jean-Pierre Bégue<sup>b</sup>

<sup>a</sup>Laboratory of Organic and Bioorganic Chemistry, 'Jozef Stefan' Institute, Jamova 39, Slovenia

<sup>b</sup>BIOCIS UPRES-A 8079, Faculté de Pharmacie, Université Paris-Sud, Chatenay-Malabry, France

Received 21 May 2003; revised 13 June 2003; accepted 14 June 2003


**Abstract**—1,2,4,5-Tetraoxanes, potent antimalarial drugs, were selectively synthesized in fluorous alcohols (2,2,2-trifluoroethanol–TFE and 1,1,1,3,3,3-hexafluoro-2-propanol–HFIP). A use of these solvents enabled for the first time a one-pot synthesis of non-symmetric tetraoxanes in good yields from simple ketones and aldehydes with 2 equiv. of 30% hydrogen peroxide and 0.1 mol% of methyltrioxorhenium (MTO).

© 2003 Elsevier Ltd. All rights reserved.

Artemisinin and its semisynthetic derivatives represent a new class of antimalarials, active against *Plasmodium falciparum*, a chloroquine-resistant parasite, which causes several million deaths per year worldwide.<sup>1,2</sup> They contain an endoperoxide functional group as the pharmacophore and several types of synthetic cyclic peroxides were established to have good antimalarial activity.<sup>3</sup> Among them, dispiro-1,2,4,5-tetraoxanes **2** (7,8,15,16-tetraoxadispiro[5.2.5.2]-hexadecanes) exhibit remarkable antimalarial activity. They are structurally simple and easily prepared by acid-catalyzed condensation of substituted cyclohexanones and hydrogen peroxide.<sup>4–8</sup> However, until now repre-

sentatives of this group of compounds were structurally very limited and good yields of symmetric tetraoxanes **2** could be achieved only in some cases.<sup>6,9,10</sup>

Bearing in mind that symmetric tetraoxanes **2** are limited in number, non-symmetric tetraoxanes would offer more opportunity for selective incorporation of various functional groups on the tetraoxane scaffold. Very recently two methods have been reported for the synthesis of mixed tetraoxanes. They are multi-step procedures with isolation of the explosive dihydroperoxide intermediate (Scheme 1).<sup>11</sup>



Scheme 1.

<sup>☆</sup> Supplementary data associated with this article can be found at doi:10.1016/S0040-4039(03)01472-2

\* Corresponding author. Tel.: +33-146835739; fax: +33-146835740; e-mail: danièle.bonnet-delpon@cep.u-psud.fr




compound, reaction was less selective, since besides the mixed tetraoxane, both symmetric ones were formed in small quantities. Nevertheless **6b** was obtained in 45% yield after crystallization. Aliphatic as well as aromatic aldehydes could also be used for the cyclization, as may be seen in Scheme 5.


Having established that the  $\text{H}_2\text{O}_2$ /MTO/fluorous alcohol oxidative system quantitatively converts aldehydes into symmetrical tetraoxanes with only 1 equiv. of 30%  $\text{H}_2\text{O}_2$  and 0.1 mol% of MTO, we tried to extrapolate to the synthesis of mixed tetraoxanes with the basic carbonyl unit of an aldehyde and the secondary one of an aliphatic ketone. Reaction was performed with octanal and 2 equiv. of  $\text{H}_2\text{O}_2$  and 0.1 mol% of MTO in HFIP (rt, 1 h) followed by the addition of 2 equiv. of 5-nonanone and 1 equiv. of  $\text{HBF}_4$  (rt, 1 h). Again, mixed tetraoxane **7** was obtained in 51% isolated yield after column chromatography and crystallization (Scheme 6).

**Conclusion.** The use of the  $\text{H}_2\text{O}_2$ /MTO/fluorous alcohol system enables for the first time a one-pot and selective synthesis of non-symmetric tetraoxanes in good yields. Therefore isolation of the intermediate product, the *gem*-dihydroperoxide, is no longer necessary, representing a great improvement because of its unstable and explosive nature. The use of fluorous alcohols as solvents brings further advantages: the use of an excess of  $\text{H}_2\text{O}_2$  is no longer required, the amount of catalyst is low (0.1 mol%), and finally, the cyclization step is highly selective since formation of trimeric cyclic peroxides (hexaoxonanes) was completely avoided, tetraoxanes being the only reaction products (Scheme 7).

Available tetraoxanes as a group of compounds were so far structurally limited. However, with this new method it is now possible to synthesize structurally diverse tetraoxanes and consequently selectively manipulate peroxide functionality. This will give a strong impetus to research on these antimalarials, and on their structure/activity relationship.



Scheme 6.



Scheme 7.

**Supporting information.** Experimental procedures and full characterization for compounds **2**, **4**, **5**, **6** and **7**.

## Acknowledgements

This research was supported by the European Community Human Potential Programme Marie Curie Individual Fellowship (J.I.) under contract number HPMF-CT-1999-00097 and GDR Parasitology. We are grateful to Dr. Dusan Zigon and Dr. Bogdan Kralj for MS measurements and Michèle Ourévitch for the help with NMR spectra.

## References

1. Malaria Foundation International, <http://www.malaria.org>.
2. (a) Haynes, R. K.; Vonwiller, S. C. *Acc. Chem. Res.* **1997**, *30*, 73–79; (b) Robert, A.; Dechy-Cabaret, O.; Cazelles, J.; Meunier, B. *Acc. Chem. Res.* **2002**, *35*, 167–174; (c) Wu, Y. K. *Acc. Chem. Res.* **2002**, *35*, 255–259.
3. McCullough, K. J.; Nojima, M. *Curr. Org. Chem.* **2001**, *5*, 601–636.
4. (a) Dong, Y. X.; Matile, H.; Chollet, J.; Kaminsky, R.; Wood, J. K.; Vennerstrom, J. L. *J. Med. Chem.* **1999**, *42*, 1477–1480; (b) Vennerstrom, J. L.; Fu, H. N.; Ellis, W. Y.; Ager, A. L.; Wood, J. K.; Andersen, S. L.; Gerena, L.; Milhous, W. K. *J. Med. Chem.* **1992**, *35*, 3023–3027; (c) Vennerstrom, J. L.; Ager, A. L.; Andersen, S. L.; Grace, J. M.; Wongpanich, V.; Angerhofer, C. K.; Hu, J. K.; Wesche, D. L. *Am. J. Trop. Med. Hyg.* **2000**, *62*, 573–578; (d) Vennerstrom, J. L.; Dong, Y. X.; Andersen, S. L.; Ager, A. L.; Fu, H. N.; Miller, R. E.; Wesche, D. L.; Kyle, D. E.; Gerena, L.; Walters, S. M.; Wood, J. K.; Edwards, G.; Holme, A. D.; McLean, W. G.; Milhous, W. K. *J. Med. Chem.* **2000**, *43*, 2753–2758.
5. Jefford, C. W.; Boukouvalas, A. J. *J. Synthesis* **1988**, 391–393.
6. Kim, H. S.; Shibata, Y.; Wataya, Y.; Tsuchiya, K.; Masuyama, A.; Nojima, M. *J. Med. Chem.* **1999**, *42*, 2604–2609.
7. McCullough, K. J.; Wood, J. K.; Bhattacharjee, A. K.; Dong, Y. X.; Kyle, D. E.; Milhous, W. K.; Vennerstrom, J. L. *J. Med. Chem.* **2000**, *43*, 1246–1249.
8. (a) Opsenica, D.; Pocsfalvi, G.; Juranic, Z.; Tinant, B.; Declercq, J. P.; Kyle, D. E.; Milhous, W. K.; Solaja, B. A. *J. Med. Chem.* **2000**, *43*, 3274–3282; (b) Todorovic, N. M.; Stefanovic, M.; Tinant, B.; Declercq, J. P.; Makler, M. T.; Solaja, B. A. *Steroids* **1996**, *61*, 688–696.
9. Dong, Y. X.; Vennerstrom, J. L. *J. Org. Chem.* **1998**, *63*, 8582–8585.
10. Ito, Y.; Yokoya, H.; Umehara, Y.; Matsuura, T. *Bull. Chem. Soc. Jpn.* **1980**, *53*, 2407–2408.
11. (a) Kim, H. S.; Tsuchiya, K.; Shibata, Y.; Wataya, Y.; Ushigoe, Y.; Masuyama, A.; Nojima, M.; McCullough, K. J. *J. Chem. Soc., Perkin Trans. 1* **1999**, 1867–1870; (b) Solaja, B. A.; Terzic, N.; Pocsfalvi, G.; Gerena, L.; Tinant, B.; Opsenica, D.; Milhous, W. K. *J. Med. Chem.* **2002**, *45*, 3331–3336.

12. (a) Ravikumar, K. S.; Zhang, Y. M.; Bégué, J. P.; Bonnet-Delpon, D. *Eur. J. Org. Chem.* **1998**, 2937–2940; (b) Legros, J.; Crousse, B.; Bourdon, J.; Bonnet-Delpon, D.; Bégué, J. P. *Tetrahedron Lett.* **2001**, 42, 4463–4466; (c) van Vliet, M. C. A.; Arends, I. W. C. E.; Sheldon, R. A. *Synlett* **2001**, 248–250; (d) ten Brink, G.-J.; Vis, J. M.; Arends, I. W. C. E.; Sheldon, R. A. *Tetrahedron* **2002**, 58, 3977–3983; (e) Neimann, K.; Neumann, R. *Org. Lett.* **2000**, 2, 2861–2863; (f) Berkessel, A.; Andreae, M. M. *Tetrahedron Lett.* **2001**, 42, 2293–2295; (g) Berkessel, A.; Andreae, M. R. M.; Schmickler, H.; Lex, J. *Angew. Chem., Int. Ed.* **2002**, 41, 4481–4484; (h) de Visser, S. P.; Kaneti, J.; Neumann, R.; Shaik, S. *J. Org. Chem.* **2003**, 68, 2903–2912.
13. (a) Iskra, J.; Bonnet-Delpon, D.; Bégué, J. P. *Tetrahedron Lett.* **2002**, 43, 1001–1003; (b) van Vliet, M. C. A.; Arends, I. W. C. E.; Sheldon, R. A. *Chem. Commun.* **1999**, 821–822.
14. Iskra, J.; Bonnet-Delpon, D.; Bégué, J. P. *Eur. J. Org. Chem.* **2002**, 3402–3410.
15. Dong, Y. X.; Vennerstrom, J. L. *J. Heterocycl. Chem.* **2001**, 38, 463–466.